+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07500220

Phase 12 Study of Dual-Target GPC3 and B7-H3 CAR-NK Cell Therapy for Adults with Advanced or Metastatic Hepatocellular Carcinoma

Led by Beijing Biotech · Updated on 2026-03-30

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an investigational allogeneic dual-target CAR-NK cell therapy aimed at treating adults with advanced hepatocellular carcinoma HCC. This therapy targets two antigens, GPC3 and B7-H3, to address tumor cell heterogeneity and reduce antigen escape. The study is designed as a phase 12 open-label trial focusing first on safety and dose-limiting toxicities, then expanding at the recommended phase 2 dose to estimate preliminary anti-tumor activity. It addresses a patient population with unresectable, relapsedrefractory, or metastatic HCC who have limited treatment options. Participants receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide before an intravenous infusion of the genetically engineered CAR-NK cells. The trial uses a dose-escalation approach in phase 1 to find the safe dose, followed by a dose-expansion phase 2 at the recommended dose. Close monitoring for infusion reactions, cytokine release syndrome, neurotoxicity, hepatotoxicity, cytopenias, infections, and off-tumor effects is implemented throughout the study. During the study, participants undergo serial imaging and translational assessments such as CAR-NK cell persistence, serum AFP levels, cytokine profiling, and circulating tumor DNA dynamics. Safety is monitored for at least 12 months, including tracking dose-limiting toxicities and adverse events. Efficacy outcomes include response rates, disease control, duration of response, progression-free survival, and overall survival. The total participation duration varies with these assessments and ongoing safety follow-up.

CONDITIONS

Brief Title

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Research Team

S

Seni S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here